Patents by Inventor Mark Kris

Mark Kris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190145987
    Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).
    Type: Application
    Filed: April 21, 2017
    Publication date: May 16, 2019
    Inventors: Eizirik Decio LAKS, Alexander BALHUIZEN, Nick Mark DEVOOGDT, Sam Marc Kris Aimé MASSA, Luc BOUWENS, Iris MATHIJS
  • Patent number: 7310443
    Abstract: A method for the automatic detection and correction of red eye in a digital image is disclosed. The method includes defining a digital image in a hue-saturation-intensity (HSI) color space, and identifying a red eye region in a digital image. Using HSI criteria, identified regions are filtered to discard areas unlikely to be the result of red eye effect, and then a plurality of algorithms are used to apply a color correction to each pixel in the identified red eye region. The color correction manipulates each pixel of the red eye region remove the red eye effect. The method is automatic, and requires no input from a user to define the red eye region, to identify the true color of the red eye region, or to apply the color correction.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: December 18, 2007
    Assignee: Sonic Solutions, Inc.
    Inventors: Mark Kris, Mikhail Mironov
  • Publication number: 20050281822
    Abstract: Methods for treating a human patient suffering from malignant pleural effusion by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF trap protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.
    Type: Application
    Filed: June 17, 2005
    Publication date: December 22, 2005
    Inventors: Jesse Cedarbaum, Christopher Azzoli, Mark Kris, Jakob Dupont